Obesity Rates by US State Context While national obesity rates are declining, significant geographic variation remains
While this provides excellent measurement precision, it results in larger injection volumes
Adjusting the dose is a step-by-step process guided by healthcare professionals only
In April 2026, the FDA proposed excluding semaglutide from the 503B bulks list, which would shut down most remaining compounding supply
Wegovy (semaglutide) Injector is a prescription medication used to treat obesity in adults who have a body mass index (BMI) of 30 kg/m or greater, or in adults with a BMI of 27 kg/m or greater who also have at least one weight-related medical condition, such as high blood pressure, type 2 diabetes, or high cholesterol
Other patients report a bit of stomach discomfort but thats it